Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.

@article{Zinzani1996MonitoringBM,
  title={Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.},
  author={Pier Luigi Zinzani and Maurizio Zompatori and Maurizio Bendandi and Giuseppe Battista and Stefano Fanti and Enza Barbieri and Filippo Gherlinzoni and Maria Rita Rimondi and Giovanni Frezza and Paolo Pisi and Emanuela Merla and Alessandro Gozzetti and Romeo Canini and N. C. Monetti and L Babini and Sante Tura},
  journal={Leukemia & lymphoma},
  year={1996},
  volume={22 1-2},
  pages={131-5}
}
Treatment of both Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL) with bulky presentation at diagnosis frequently results in residual masses detected radiologically. Conventional diagnostic radiology and computed tomography (CT) are generally unable to detect the differences between tumor tissue and fibrosis. Gallium-67-citrate (67Ga) SPECT and magnetic resonance imaging (MRI) can potentially differentiate residual active tumor tissue and fibrosis. Thirty-three patients… CONTINUE READING